Shanghai, China, May 20, 2021 – Asieris Pharmaceuticals (Asieris) announced today that it has signed a strategic collaboration agreement with Sinopharm. The two companies will jointly advance commercialization, logistics and supply chain services for the innovative products of Asieris. The first project under the partnerhsip will be the commercialization of Hexvix®, which comes on the heels of the collaboration with Lecheng Sinopharm.
Asieris focuses on genitourinary tumors and related diseases, striving to build a leading portfolio and develop integrated solutions of diagnosis and treatment for the best care of our patients. Hexvix® is the only optical imaging agent indicated for use in the cystoscopic detection of bladder cancer. The use of Hexvix® with Blue Light Cystoscopy (BLC®) can effectively improve the detection of non-muscle invasive bladder cancer (NMIBC), especially carcinoma in situ. Hexvix® has been marketed in more than 30 countries. Asieris obtained the exclusive rights to register and commercialize Hexvix® in Mainland China and Taiwan in January this year.
“We are delighted to be working with a global innovative company like Asieris,” said Mr. Yong Liu, President of Sinopharm. “Sinopharm has an extensive pharmaceutical marketing network and strong market service capabilities. We will take full advantage of the brand, channels and networks to benefit more bladder cancer patients with innovative medicines, and contribute to the development of the healthcare industry in China.”
“Sinopharm is a corporate champion in the healthcare services sector,” said Kevin Pan, Ph.D., Founder and CEO of Asieris. “Leveraging the strong network and coverage of Sinopharm, we look forward to helping Chinese patients have easier and faster access to innovative drugs like Hexvix®. As a next generation fluorescent agent for cystoscopy, Hexvix® is also an ideal synergistic product with our existing pipeline to support our strategy of developing an integrated diagnosis and treatment solution for genitourinary cancers, thereby contributing to the Healthy China Initiative. “
About Sinopharm
Sinopharm Group Co. Ltd. was established in January 2003 which is a core subsidiary of China National Pharmaceutical Group Co., Ltd. (“CNPGC”) and the largest wholesaler and retailer of pharmaceutical and healthcare products and medical devices, and a leading supply-chain service provider in the PRC. The Group provides comprehensive distribution, logistics and other value-added services to domestic and foreign manufacturer and suppliers of pharmaceutical products, medical devices and consumables and other healthcare products, and also to downstream customers including hospitals, other distributors, retail drug stores and primary health services institutions.
About Asieris
Asieris Pharmaceuticals, founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus. Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
